-
Mashup Score: 2Study launches of 225Ac-PSMA-Trillium in mCRPC - 4 day(s) ago
“225Ac-PSMA-Trillium is a novel approach, which could provide a new treatment to address this unmet need in mCRPC,” says Fred Saad, MD, FRCS.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Innovation fund to bolster adoption of prostate cancer test - 19 day(s) ago
The test, which was launched in Canada in September 2023, is available through Nanostics’ accredited laboratory in Edmonton, Alberta.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Study progresses of NK cell therapy in mCRPC - 20 day(s) ago
All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study to the second dose level of INKmune.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Dr. Pienta on the evolving paradigm of PSMA-PET imaging - 29 day(s) ago
“The advance of PSMA imaging has put an emphasis on multidisciplinary care,” says Kenneth J. Pienta, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,” says Stephen Rose, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Trial of ONCT-534 in mCRPC progresses to higher dose level - 1 month(s) ago
“We look forward to announcing initial efficacy and safety data from the study, which we expect will be at the end of this quarter,” says Salim Yazji, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Expert discusses meta-analysis of prostate radiotherapy - 1 month(s) ago
“In my view, at present in patients that have low-volume oligometastatic de novo metastatic prostate cancer, it’s really an unknown whether comprehensive SBRT or other local therapy directed at oligomets improves survival,” says Scott Morgan, MD, MSc, FRCPC.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2212Pb SPECT/CT imaging shows initial benefit, feasibility in mCRPC - 1 month(s) ago
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,” says Stephen Rose, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Dr. Scott Morgan on meta-analysis evaluating prostate RT in mHSPC - 1 month(s) ago
“In our analysis, the highest ranked treatment strategy was the combination of standard of care systemic therapy, an AR pathway inhibitor, and prostate radiotherapy,” says Scott Morgan, MD, MSc, FRCPC.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Treatment begins in study of gedatolisib plus darolutamide in mCRPC - 3 month(s) ago
The CELC-G-201 trial is assessing the safety, preliminary efficacy, and pharmacokinetics of gedatolisib plus darolutamide in mCRPC
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
Dosing has commenced in a phase 1 study exploring the safety, tolerability, and preliminary efficacy of 225Ac-PSMA-Trillium in mCRPC. #pcsm #prostatecancer #urology https://t.co/op6ZQtpYnL